Welcome to our dedicated page for Biofrontera news (Ticker: BFRIW), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. (Nasdaq: BFRI, warrants Nasdaq: BFRIW) generates a steady flow of news centered on its dermatology-focused photodynamic therapy (PDT) business. Company press releases highlight commercial performance for Ameluz® PDT, progress in clinical development, and key corporate and regulatory milestones, offering context for both the underlying common stock and the associated BFRIW warrants.
Recent announcements describe record preliminary quarterly revenues, with management attributing growth to sales execution of Ameluz PDT and pricing changes. Biofrontera also reports on clinical trial milestones, such as database locks for a Phase 3 study in actinic keratosis on the extremities, neck and trunk and a Phase 2 study in moderate to severe acne vulgaris, as well as completion of a Phase 1 pharmacokinetics study in peripheral body areas. These updates are framed as supporting future regulatory submissions and potential label expansions.
News items further cover regulatory and intellectual property developments, including submission of a supplemental New Drug Application for superficial basal cell carcinoma and the completion of transfers of FDA approvals, patents, and trademarks for Ameluz and the RhodoLED lamp series to Biofrontera Inc. Corporate and financing news, such as the restructuring of the relationship with Biofrontera AG, preferred stock financings, and the divestiture of the Xepi antibiotic cream license, also appear in the company’s disclosures.
Visitors to this BFRIW news page can review earnings releases, business updates, clinical and regulatory announcements, and transaction-related press releases that collectively illustrate how Biofrontera is advancing its PDT platform in dermatology. For investors following the BFRIW warrants, these news items provide insight into the operating and strategic developments of the underlying issuer, Biofrontera Inc.
Biofrontera Inc. (Nasdaq: BFRI) will announce its financial results for Q1 2022 on May 13, 2022, prior to U.S. market opening. A conference call is scheduled for the same day at 11:00 a.m. ET to discuss the results and provide a business update. The company specializes in dermatological treatments, focusing on photodynamic therapy and topical antibiotics. Its licensed products treat actinic keratoses and impetigo.
Biofrontera (Nasdaq: BFRI) announced its sponsorship of the 17th Music City Symposium for Cosmetic Advances & Laser Education, held May 11-15, 2022, in Nashville. This event marks the first domestic showcase of its FDA-approved RhodoLED® XL illumination lamp for photodynamic therapy (PDT). Dr. Michael Gold will present a live demonstration during the symposium. Biofrontera aims to promote its products and strengthen medical initiatives, participating in events supporting Skin Cancer Awareness Month. The company remains on track to launch RhodoLED® XL by the year-end.
Biofrontera Inc. (Nasdaq: BFRI) announced the launch of new and enhanced websites for its products, Ameluz® and Xepi®. The websites feature a dual structure catering to both patients and healthcare professionals, aimed at improving accessibility and brand awareness. CEO Erica Monaco emphasized the importance of educating the industry about photodynamic therapy's efficacy. The patient-oriented Xepi® site includes information on pharmacy access and co-pay programs, while Ameluz®'s site provides comprehensive treatment details, including prescribing information. This initiative is part of a broader strategy to expand market presence.
Biofrontera (Nasdaq: BFRI) announced FDA approval for its cGMP laboratory in Leverkusen, Germany, enhancing manufacturing efficiency and quality control for Ameluz (aminolevulinic acid hydrochloride gel, 10%). This clearance enables impurity testing to be performed in-house, reducing reliance on third-party suppliers and mitigating production risks. The company aims to optimize commercial supply of Ameluz and its associated PDT-lamps in the U.S. market, thus streamlining operations and ensuring consistent product quality.
Biofrontera Inc. (Nasdaq: BFRI) reported a 28% revenue increase for 2021, reaching $24.1 million, with Q4 revenues at $9.2 million, up 7% year-over-year. Despite growth, the company faced a net loss of $37.7 million for the year. Cash reserves stood at $24.5 million, sufficient for operations through 2023. Biofrontera initiated two clinical studies for Ameluz® and aims for over 30% revenue growth in 2022, boosted by strong sales momentum and a focus on customer penetration. The company also received U.S. patents and regulatory approvals, enhancing its market position.
Biofrontera (Nasdaq: BFRI) reported preliminary product revenues for Q1 2022, forecasting between $9.5 million and $10.0 million, an increase of approximately 102% to 113% year-over-year. CEO Erica Monaco highlighted this growth as evidence of the market's preference for their products. The revenue surge is partly attributed to advance purchases before a planned price hike. The final results will be disclosed in May 2022, with caution expressed about the potential for variance in estimates.
Biofrontera Inc. (Nasdaq: BFRI) announced it will report its financial results for Q4 and the full year ended December 31, 2021, on April 8, 2022, prior to the opening of U.S. markets. The company will host a conference call at 11:00 a.m. ET the same day to discuss these results and provide a business update.
The call can be accessed through a toll-free number for U.S. participants and an international line. A webcast of the call will also be available for live viewing and a 90-day replay.
Biofrontera Inc. (Nasdaq: BFRI) will prominently showcase its FDA-approved dermatological products at the AAD Annual Meeting from March 25-29, 2022, in Boston, with an expected attendance of 10,000 medical professionals. CEO Erica Monaco highlights the event's significance for enhancing visibility and promoting photodynamic therapy (PDT) for actinic keratoses. The company's booth will feature its flagship drug Ameluz® and Xepi®, aiming to strengthen connections with dermatologists and industry leaders. This participation aligns with Biofrontera's growth strategy in dermatology.
Biofrontera (Nasdaq: BFRI) announced that its U.S. patent No. 11,235,169 for the BF-RhodoLED® XL illumination device is now included in the FDA's Orange Book. This patent protects Ameluz®-PDT through October 2040, serving as a barrier against generic competition. The FDA's listing confirms the patent's role in safeguarding the approved drug-device combination. The CEO, Erica Monaco, stated that this endorsement strengthens their market position. Additionally, two new patents for BF-RhodoLED® XL were granted, emphasizing the company's strategy to secure its competitive advantage.
Biofrontera Inc. (Nasdaq: BFRI) has announced that CEO Erica Monaco will present at the 34th Annual Roth Conference from March 13-15, 2022, in Laguna Niguel, California. During the event, scheduled for March 15 at 11:00 AM PT, Monaco will engage with registered investors through meetings and presentations. The conference features various growth sector discussions, including healthcare and technology. A live audio webcast of Biofrontera's presentation will be accessible on the company's investor relations website.